Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2013

View Archived Issues

Development of a fusion glycoprotein antiviral vaccine using structure-based design

Characterization of novel cocaine metabolizing enzymes for treatment of addiction

Noninvasive diagnostic agent for early detection of pulmonary hypertension reported

Preliminary data detailed for a novel H3 receptor antagonist for allergic nasal congestion

Melior licenses oral insulin sensitizer to Bukwang in Asia-Pacific region

CSL enters agreement with Janssen for CSL-362

First-in-human phase I study reported for SGN-CD19A

Development of novel 5-HT2C PAMs for neurological disorders

Genocea Biosciences begins phase I study of GEN-004

RP-6530 phase I study begins in advanced hematological malignancies

Baxter files for pediatric indication of Rixubis with the FDA

FDA accepts NDA filing of NEPA

GSK and Theravance report results from phase III asthma therapy trial

ZIOPHARM Oncology to begin phase I study of Ad-RTS-IL-12

Heptares initiates first clinical study of fully selective M1 receptor agonist

New tyrosine-protein kinase inhibitors disclosed by Novartis

Canadian approval for Bexsero meningococcal B vaccine

Shire reports data from second phase III study of lifitegrast for dry eye disease

Enanta Pharmaceuticals synthesizes novel NS3 inhibitors for HCV Infection

Phase III study of panobinostat in multiple myeloma meets primary endpoint

Chinese group patents novel 5-HT1A receptor and SERT ligands

Relvar Ellipta now available in Japan

New HSP 90 inhibitors disclosed by U.S. groups

Simeprevir launched in Japan, Canada and U.S.

FDA committee recommends approval of vedolizumab for ulcerative colitis and Crohn's disease

Sanofi synthesizes novel LPA5 receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...